- Location
chronic lymphocytic leukemia
"-
A New Combination of Drugs Might Prolong Life in Certain Older Leukemia Patients
Jan 10, 2014A new combination of drugs might prolong life in certain older leukemia patients, a new study suggests. The research, led by German scientists, included nearly 800 older people (average age 73) who had been diagnosed with chronic ...
Tags: Drug, Drug Combo, Leukemia
-
Gene Therapy Might Be a Powerful Weapon Against Leukemia and Other Blood Cancers
Dec 26, 2013Preliminary research shows that gene therapy might one day be a powerful weapon against leukemia and other blood cancers. The experimental treatment coaxed certain blood cells into targeting and destroying cancer cells, according to ...
Tags: gene therapy, leukemia, blood cancer
-
The US Food and Drug Administration Has Granted Orphan Drug Status
Dec 5, 2013The US Food and Drug Administration (FDA) has granted orphan drug status for Teva Pharmaceutical's Treanda injection through October 2015 for indolent B-cell non-Hodgkin lymphoma (iNHL) that has progressed during or within six months of ...
-
Viteava Pharmaceuticals Announced The Execution of an Exclusive Worldwide License
Nov 21, 2013Viteava Pharmaceuticals has announced the execution of an exclusive worldwide license to an intellectual property portfolio claiming composition of matter and/or methods of use of novel analogs and derivatives of the green tea flavonoid, ...
Tags: exclusive worldwide license, EGCG, Viteava Pharmaceuticals
-
FDA Approved Roche's Drug Gazyva in Combination with Chlorambucil Chemotherapy
Nov 5, 2013The US Food and Drug Administration (FDA) has approved Roche's new drug Gazyva (obinutuzumab) in combination with chlorambucil chemotherapy for treatment of patients with chronic lymphocytic leukemia (CLL) who have not previously been ...
Tags: Combination Vaccine, Medicine
-
Janssen-Cilag Has Submitted MAA to EMA
Nov 1, 2013Janssen-Cilag (Janssen), a subsidiary of Johnson & Johnson pharmaceutical firm, has submitted marketing authorization application (MAA) to the European Medicines Agency (EMA) for the approval of once daily oral drug ibrutinib for the ...
Tags: Blood Cancer Medicine, Medicine
-
GSK Has Submitted a NDA to The US FDA for The Once Daily ICS Treatment
Oct 28, 2013GlaxoSmithKline (GSK) has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA dry powder ...
Tags: Asthma Treatment, Medicine
-
GSK and Danish Biotechnology Firm Genmab Have Filed a Supplemental Agreement
Oct 22, 2013GlaxoSmithKline (GSK) and Danish biotechnology firm Genmab have filed a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for the use of its leukaemia drug Arzerra (ofatumumab) in combination ...
Tags: GlaxoSmithKline, CLL Patients
-
Danish Biotechnology Firm Genmab Has Unveiled Positive Results From a Phase II Study
Oct 12, 2013Danish biotechnology firm Genmab has unveiled positive results from a Phase II study of its sclerosis drug candidate ofatumumab in relapsing-remitting multiple sclerosis (RRMS). In a randomized study of 232 patients with RRMS, treatment ...
Tags: Genmab, Sclerosis Drug
-
The FDA Has Approved Breakthrough Therapy Designation for Genmab and Arzerra
Sep 17, 2013The US Food and Drug Administration (FDA) has approved breakthrough therapy designation for Danish biotechnology company Genmab and British pharmaceutical company GlaxoSmithKline’s (GSK) Arzerra (ofatumumab) in combination with ...
Tags: therapy designation, Medicine
-
NDA for The Investigational Oral BTK Inhibitor,Ibrutinib,Has Been Accepted by The US FDA
Sep 2, 2013Clinical-stage biopharmaceutical company Pharmacyclics' new drug application (NDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been accepted by the US FDA for two B-cell malignancy indications. ...
Tags: Solvay Group, Medicine
-
Janssen Research & Development Is Seeking FDA Approval for Use Ibrutinib in The Treatment
Jul 12, 2013Janssen Research & Development is seeking FDA approval for use of ibrutinib in the treatment of previously treated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). The ...
Tags: FDA Approval, Janssen
-
Genentech Obtained FDA Priority Review Status for GA101 to Treat CLL
Jul 5, 2013Genentech, a member of the Roche Group, has obtained FDA priority review status for Obinutuzumab (GA101) to treat previously untreated chronic lymphocytic leukemia (CLL). The FDA has also accepted the company's biologics license ...
Tags: Genentech, FDA Priority
-
Abbott Has Entered Into a Collaboration Agreement
Feb 25, 2013Abbott has entered into a collaboration agreement with Janssen Biotech and Pharmacyclics to develop a molecular companion diagnostic test for investigational leukemia therapy. Under the agreement, Abbott will leverage its proprietary ...
Tags: leukemia therapy, Abbott, Pharmacyclics
-
Clonosight Mrd Test Is Introduced by Sequenta
Feb 19, 2013Sequenta has introduced a sequencing-based test for minimal residual disease (MRD) for leukemia and lymphoma. The ClonoSIGHT test utilizes the company's proprietary LymphoSIGHT technology, which works by sequencing DNA signatures that are ...
Tags: Sequenta, sequencing-based test, minimal residual disease
